Highlights
- In metabolic dysfunction-associated steatotic liver disease (MASLD), hepatic HSP72 levels were reduced in both mouse models and human liver samples, and this decline tracked with impaired mitophagy.
- Loss of HSP72, globally or in the liver, worsened steatosis and suppressed mitochondrial quality control, whereas restoring HSP72 improved mitophagy and liver disease features.
- Peroxiredoxin 6 (PRDX6) was identified as a HSP72-interacting partner that regulates ubiquitination of mitochondrial PINK1, a key step in PINK1/Parkin-dependent mitophagy.
- The study identifies Lys318 (K318) on PINK1 as a prioritized ubiquitination site in this pathway, suggesting a new mechanistic target for MASLD therapy.
Background and Clinical Context
MASLD is now recognized as one of the most common chronic liver diseases worldwide and is tightly linked to obesity, insulin resistance, type 2 diabetes, and cardiometabolic risk. Although simple steatosis may remain stable for years, a subset of patients progresses to metabolic dysfunction-associated steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. A central problem in MASLD is mitochondrial dysfunction: hepatocytes exposed to excess lipid flux accumulate damaged mitochondria, generate reactive oxygen species, and lose metabolic flexibility. When mitochondrial quality control fails, cellular injury and inflammation intensify.
Mitophagy, the selective autophagic removal of damaged mitochondria, is one of the liver’s most important defense mechanisms against this injury cascade. Among the best-characterized pathways is PINK1/Parkin-dependent mitophagy. Under mitochondrial stress, PINK1 accumulates on the outer mitochondrial membrane, recruits and activates Parkin, and triggers ubiquitin-dependent clearance of defective mitochondria. Prior experimental work has suggested that impaired mitophagy contributes to steatosis and metabolic stress, but the upstream regulators of this pathway in MASLD have remained incompletely defined.
The present study adds an important layer to that biology by placing the heat shock protein HSP72 and the redox-related enzyme PRDX6 upstream of PINK1 regulation. That is clinically interesting because both proteins sit at the intersection of proteostasis, oxidative stress, and mitochondrial quality control—three processes highly relevant to MASLD progression.
Study Design
This was a mechanistic translational study using human liver samples, MASLD mouse models, and primary mouse hepatocytes. The investigators first assessed hepatic HSP72 expression and markers of mitophagy in MASLD mice and in human tissues. They then used both global Hsp72 knockout mice and liver-specific Hsp72 knockout mice, along with HSP72 wild-type controls, to determine whether HSP72 was functionally required for mitochondrial quality control and for protection against MASLD.
In parallel, the team used isolated primary mouse hepatocytes with targeted genetic manipulation of HSP72 to validate the in vivo findings in a controlled cellular system. Co-immunoprecipitation and liquid chromatography-tandem mass spectrometry (LC-MS) were used to identify proteins that physically interact with HSP72 and might participate in mitophagy regulation. After PRDX6 emerged as a candidate, the authors examined how PRDX6 altered PINK1 ubiquitination and mapped the key ubiquitinated residue within PINK1.
Because the report is abstract-based, the precise sample sizes, statistical methods, effect sizes, and confidence intervals were not provided in the summary. That limits the ability to judge the magnitude and robustness of the observed effects, but the experimental strategy is coherent and biologically plausible.
Key Findings
MASLD was associated with suppressed mitophagy and lower HSP72 expression
The first major observation was that mitophagy was suppressed in the livers of MASLD mice and patients, and this reduction coincided with a fall in HSP72 expression. This temporal association does not prove causality on its own, but it provides a strong rationale for testing whether HSP72 actively controls mitochondrial turnover rather than simply marking cellular stress.
HSP72 loss worsened steatosis and impaired mitochondrial quality control
Both global and liver-specific deletion of Hsp72 aggravated MASLD phenotypes and further suppressed mitophagy. In practical terms, this means HSP72 appears to be protective rather than epiphenomenal. When HSP72 was restored in the liver, mitophagy was activated and MASLD was ameliorated. The same direction of effect was reproduced in primary hepatocytes, supporting a hepatocyte-intrinsic mechanism.
These findings matter because they connect a classic stress-response chaperone to mitochondrial homeostasis in a disease where energy handling is fundamentally disrupted. In a liver overloaded by lipid and oxidative stress, preserving mitochondrial integrity is likely to be metabolically advantageous.
PRDX6 was identified as the HSP72 partner linking chaperone biology to PINK1 control
Using co-immunoprecipitation and LC-MS joint analysis, the investigators identified PRDX6 as an HSP72-interacting protein associated with mitophagy. PRDX6 is best known as a multifunctional antioxidant enzyme, but here it appears to act as a signaling component rather than only a detoxifying enzyme. The study reports that PRDX6 deletion increased PINK1 ubiquitination and inhibited mitophagy, thereby worsening MASLD. Conversely, restoring PRDX6 efficiently deubiquitinated PINK1 and reactivated the mitophagy pathway.
The mechanistic significance is that HSP72 may not act alone. Instead, it seems to operate through a protein complex involving PRDX6, which then influences the ubiquitin status of PINK1. That places PRDX6 in a potentially central regulatory position within the mitochondrial surveillance machinery.
PINK1 Lys318 emerged as a key ubiquitination site
Perhaps the most detailed molecular result was the identification of lysine 318 (K318) on PINK1 as the priority ubiquitination site in response to PRDX6 regulation. Site-specific ubiquitination is important because it can determine protein localization, stability, and downstream signaling. In the context of mitophagy, the finding suggests that modulation of a single residue may meaningfully alter the fate of damaged mitochondria.
For clinicians and translational scientists, this is the most actionable insight in the report: it narrows a broad stress-response phenotype into a discrete protein interaction and a defined amino-acid target. That kind of precision is often what eventually makes a pathway druggable.
Overall pathway: HSP72/PRDX6 supports PINK1/Parkin-dependent mitophagy
Collectively, the data support a model in which reduced HSP72 in MASLD leads to impaired PRDX6-dependent regulation of PINK1, increased PINK1 ubiquitination, defective mitophagy, and worsening hepatic lipid injury. Restoring the pathway reverses these effects. The authors conclude that the HSP72/PRDX6 axis is indispensable for PINK1/Parkin-dependent mitophagy and helps counteract MASLD.
| Pathway component | Observed effect in the study | Likely biological implication |
|---|---|---|
| HSP72 | Decreased in MASLD; loss worsened disease | Protective chaperone promoting mitochondrial quality control |
| PRDX6 | Interacts with HSP72; deletion increased PINK1 ubiquitination | Upstream regulator of PINK1-dependent mitophagy |
| PINK1 K318 | Priority ubiquitination site | Critical node controlling mitophagy signaling |
| Mitophagy | Suppressed in MASLD; restored when HSP72/PRDX6 was reconstituted | Potential therapeutic mechanism for reducing lipid-induced liver injury |
Expert Commentary
This study is notable for moving beyond descriptive mitochondrial dysfunction in MASLD and identifying a defined regulatory axis. The biologic plausibility is strong. HSP72 is a canonical stress-inducible chaperone that helps maintain proteome stability under metabolic stress, while PRDX6 is linked to redox homeostasis. Their interaction provides a credible bridge between oxidative injury and mitochondrial turnover.
The work also fits with the broader literature showing that mitophagy is not merely a housekeeping process but a determinant of hepatocyte survival during lipotoxic stress. When damaged mitochondria are efficiently cleared, hepatocytes are less likely to accumulate oxidative injury, inflammatory signaling, and metabolic derangement. Conversely, impaired mitophagy can amplify the very processes that drive MASLD progression.
From a therapeutic perspective, the findings raise several possibilities. Pharmacologic induction of HSP72, enhancement of PRDX6 function, or selective stabilization of PINK1 signaling could theoretically improve mitochondrial quality control in MASLD. However, any strategy that manipulates proteostasis or ubiquitin signaling must be approached cautiously. These pathways are ubiquitous, and systemic activation could have off-target effects in muscle, immune cells, or other metabolically active tissues. Liver-specific delivery will matter.
There are also important limitations. The abstract does not provide sample sizes, baseline disease severity, quantitative histology, liver enzyme data, or metabolic endpoints such as insulin sensitivity. Without those details, it is not possible to judge effect size or translational durability. The study is also preclinical, so whether the same HSP72/PRDX6/PINK1 biology operates in advanced human MASLD, especially in fibrotic or cirrhotic livers, remains unknown. In addition, the abstract suggests that PRDX6 deubiquitinates PINK1, but the precise enzymatic mechanism warrants further clarification. Whether PRDX6 acts directly as a deubiquitinase, modulates an associated deubiquitinase, or alters the local mitochondrial environment to favor deubiquitination is an important follow-up question.
Another key issue is temporal relevance. MASLD evolves over years, and it will be important to know whether restoring this pathway can reverse established disease or only prevent early injury. Future work should also examine whether the HSP72/PRDX6 axis interacts with insulin signaling, autophagic flux, inflammasome activation, and fibrogenic pathways. Those links will determine how broadly useful this biology becomes in clinical practice.
Conclusion
The study identifies a new mechanistic checkpoint in MASLD: HSP72 interacts with PRDX6 to reduce PINK1 ubiquitination at K318, thereby restoring PINK1/Parkin-dependent mitophagy and protecting hepatocytes from metabolic injury. In experimental models, loss of this axis worsened steatosis, while restoration improved mitochondrial quality control and liver disease features.
For clinicians, the immediate message is not that HSP72 or PRDX6 is ready for use as a treatment, but that mitochondrial quality control remains a highly promising therapeutic target in MASLD. For researchers, the work provides a concrete protein-network framework that can now be tested in larger human cohorts, fibrosis models, and eventually drug-development platforms.
Funding and ClinicalTrials.gov
Funding details were not provided in the abstract summary. This is a preclinical mechanistic study, so ClinicalTrials.gov registration is not applicable.
References
- Rao Y, Su R, Cao WJ, Chen Y, Huang SH, Wu JJ, et al. HSP72 interacts with PRDX6 to deubiquitinate mitochondrial PINK1, activating mitophagy to treat MASLD. Hepatology (Baltimore, Md.). 2026-04-01. PMID: 41921676.
- Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;77(5):1966-1986.
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
- Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol. 2008;183(5):795-803.
- Lazarou M, Sliter DA, Kane LA, et al. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature. 2015;524(7565):309-314.